Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-17. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
American biochemist and geneticist at the NIH, who showed that UUU codes for phenylalanine, the first step in deciphering the genetic code. Nobel Prize in Physiology or Medicine (1968). Member Natl. Acad. Sci. USA. Roland Victor Norris (1888–1950). British biochemist at the Indian Institute of Science, who worked on glycogen metabolism and yeast fermentation, and later pioneered biochemistry in India. Paul Nurse FRS (President) (b. 1949). British geneticist at the Rockefeller University, who worked on control of the cell cycle. Nobel Prize in Physiology or Medicine (2001)
It is common in particle physics to use eV/c2 as a unit of mass. Here, eV (electronvolt) is a unit of energy (the kinetic energy of an electron accelerated over one volt, 1.6×10−19 J), and c is the speed of light in vacuum. Energy and mass are related through E = mc2. This definition is useful for a linear particle accelerator when accelerating electrons.
== See also == Body image Eating recovery Evolutionary psychiatry Idée fixe Inedia List of people with anorexia nervosa List of deaths from anorexia nervosa National Association of Anorexia Nervosa and Associated Disorders Muscle dysmorphia Orthorexia nervosa Pro-ana
SVB was a commercial bank founded in 1983 and headquartered in Santa Clara, California. At its collapse, SVB was the 16th largest bank in the U.S. by total assets and was heavily skewed toward serving companies and individuals from the technology industry. Nearly half of U.S. venture capital-backed healthcare and technology companies were financed by SVB. Companies such as Airbnb, Cisco, Fitbit, Pinterest, and Block, Inc. have been clients of the bank. In addition to financing venture-backed companies, SVB was well known as a source of private banking, personal credit lines, and mortgages to tech entrepreneurs, and specialized lending money to higher-risk new companies. Silicon Valley Bank required an exclusive relationship of those borrowing from the bank. Prior to Thursday March 9, 2023, SVB was in "sound financial condition", according to the California Department of Financial Protection and Innovation, though an increased number of short sellers began to target SVB earlier in the year. Employees received their annual bonuses on March 10, 2023, hours before the government took control of the company. As of the last call report of the bank, filed on December 31, 2022, it held $209 billion in total assets, with $175.5 billion in total deposits, of which the bank estimated $151.6 billion (86.4 percent) were uninsured.
Sources: en.wikipedia.org
== Structure and reactivity == Atractyloside is a hydrophilic glycoside. A modified glucose is linked to the hydrophobic diterpene atractyligenin by a β1-glycosidic bond. A carboxyl group is positioned at the C4 position in the axial position. The glucose part is esterified with isovaleric acid on the C2' atom, and sulfuric acid on the C3' and C4' atoms. By hydrolysis a molecule of D-(+)-glucose, isovaleric acid, atractyligenin, and two molecules of sulfuric acid could be obtained. The two sulfate groups and the carboxyl group in ATR are in a deprotonated form under physiological conditions. Thus, ATR is triple negatively charged.
However, it may have been for religious reasons, and would coincide with the development of religious practices thought to have occurred during the Upper Paleolithic. Nonetheless, it remains possible that Paleolithic societies never practiced cannibalism, and that the damage to recovered human bones was either the result of excarnation or predation by carnivores such as saber-toothed cats, lions, and hyenas. A modern-day diet known as the Paleolithic diet exists, based on restricting consumption only to those foods presumed to be available to anatomically modern humans prior to the advent of settled agriculture.
Existential risk researchers analyze risks that could lead to human extinction or civilizational collapse, and look for ways to build resilience against them. Relevant research centers include the Cambridge Center for the Study of Existential Risk and the Stanford Existential Risk Initiative. Future technologies may contribute to the risks of artificial general intelligence, biological warfare, nuclear warfare, nanotechnology, anthropogenic climate change, global warming, or stable global totalitarianism, though technologies may also help to mitigate asteroid impacts and gamma-ray bursts. In 2019, philosopher Nick Bostrom introduced the notion of a vulnerable world, "one in which there is some level of technological development at which civilization almost certainly gets devastated by default", citing the risks of a pandemic caused by bioterrorists, or an arms race triggered by the development of novel armaments and the loss of mutual assured destruction. He invites policymakers to question the assumptions that technological progress is always beneficial, that scientific openness is always preferable, or that they can afford to wait until a dangerous technology has been invented before they prepare mitigations.
These churches provide a space for worship and community support for those who have left the Druze faith. Prominent converts from the Druze faith to Christianity include: Mohamed Alí Seineldín, Nada Nadim Prouty, Selwa Carmen Showker "Lucky" Roosevelt, and others.
Another report also published by the European Union Drugs Agency that conducted an analysis of wastewater samples for the presence of drug use in cities across Europe, found that more than 75% of cities had higher concentrations of cocaine and MDMA in wastewater during weekends indicating that these drugs are more often used in nightlife and recreational settings. It also found that of the cities tested about half of them found that ketamine use spiked on weekends. The same analysis of wastewater also found that cannabis, amphetamine and methamphetamine appear consistently throughout the week suggesting that people may use these drugs daily or for a non-recreational use.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.